Repligen Corporation Aktie News

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effec...

WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesda...

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company's growing proteins portfolio an...

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Decem...

Repligen Corporation ( RGEN ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. Good afternoon, everybody.

Repligen Corporation ( RGEN ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Presentation Matthew Stanton Jefferies LLC, Research Division Thanks. My name is Matt Stanton.

Repligen stands out as a leading bioprocess supplier, benefiting from secular growth in biologics and industry patent expirations. RGEN's strong balance sheet, recurring organic growth, and strategic acquisitions position it for continued outperformance despite sector volatility. The current depressed valuation and stable financials make RGEN attractive for long-term investors seeking bioproces...